CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SETTLEMENT AND TERMINATION OF LICENSE AGREEMENTTermination of License Agreement • May 16th, 2022 • Aytu Biopharma, Inc • Pharmaceutical preparations • New York
This Settlement and Termination of License Agreement (the “Settlement Agreement”) is made as of May 12, 2022 (the “Settlement Effective Date”), by and between Aytu BioPharma, Inc. (formerly known as Aytu BioScience, Inc.), a Delaware corporation, with its principal offices at 373 Inverness Parkway, Suite 206, Englewood, CO (“Aytu”), and TRIS Pharma, Inc., a New Jersey corporation, with a location at 2031 U.S. Highway 130, Monmouth Junction, NJ 08852 (“TRIS”) (collectively, the “Parties”).
